CD8 (T cells)

Ongoing clinical trials and approved products targeting CD8 (T cells), in radioligand therapy and PET/SPECT imaging. Data as of 26 October 2026.

0ongoing therapy trials

6ongoing imaging trials

0approved products

Target note

Full name: CD8 receptor
Nature: Co-receptor of cytotoxic T lymphocytes.
Normal expression: Spleen, bone marrow, lymph nodes.
Value: Quantifying the tumor CD8 T-cell infiltrate, predictive of the response to immunotherapy.
Approaches: [89Zr]crefmirlimab (minibody), [68Ga] anti-CD8 nanobodies.
Indications explored: Solid tumors under immunotherapy.
Points of caution: Physiological lymphoid uptake.

Ongoing imaging trials · 6Open in the radar →

Trial	Phase	Status	Sponsor	Countries
CD8 tracers (T cells)2024-515885-15-00 · Solid tumors (multiple indications)	Phase 2	Recruiting	Universitair Medisch Centrum Groningen	2
CD8 tracers (T cells)2024-514489-38-01 · Atherosclerosis and vessels	Phase 2	Recruiting	Universitair Medisch Centrum Groningen	1
CD8 tracers (T cells)NCT06650163 · Meningioma	Phase 1	Recruiting	Jonsson Comprehensive Cancer Center	1
CD8 tracers (T cells)NCT05279027 · Melanoma	Phase 1	Active, not recruiting	Abramson Cancer Center at Penn Medicine	1
CD8 tracers (T cells)NCT05371132 · Lymphoma	Phase 1	Recruiting	City of Hope Medical Center	1
CD8 tracers (T cells)NCT07608627 · Pancreas (adenocarcinoma)	Phase 1	Not yet recruiting	City of Hope Medical Center	1

Cite this page

CD8 (T cells). Theranostic Atlas, LaRadiopharmacie.fr. Data as of 26 October 2026. https://theranosticatlas.com/target/cd8-t-cells/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.